-
EP3999087
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3999087
| EP3999087 - SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 22.04.2022 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 29.01.2021 | Most recent event Tooltip | 29.07.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states The Trustees of Columbia University in the City of New York West 116th Street and Broadway New York New York 10027 / US | For all designated states Seneca Therapeutics, Inc. 202 St. Andrews Court Blue Bell, PA 19422 / US | [2022/21] | Inventor(s) | 01 /
RACANIELLO, Vincent R. 1211 Cooper Road Scotch Plains, NJ 97976 / US | 02 /
ROSENFELD, Amy B. 344 Fort Washington Apartment 2A New York, NY 10033 / US | 03 /
HALLENBECK, Paul L. 202 St. Andrews Court Blue Bell, PA 19422 / US | [2022/21] | Representative(s) | D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [N/P] |
| Former [2022/21] | D Young & Co LLP 120 Holborn London EC1N 2DY / GB | Application number, filing date | 20843259.1 | 20.07.2020 | [2022/21] | WO2020US42795 | Priority number, date | US201962876191P | 19.07.2019 Original published format: US 201962876191 P | [2022/21] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021016194 | Date: | 28.01.2021 | Language: | EN | [2021/04] | Type: | A1 Application with search report | No.: | EP3999087 | Date: | 25.05.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.01.2021 takes the place of the publication of the European patent application. | [2022/21] | Search report(s) | International search report - published on: | US | 28.01.2021 | (Supplementary) European search report - dispatched on: | EP | 21.07.2023 | Classification | IPC: | A61K35/768, A61P35/00, C12N15/36, C12N15/74 | [2022/21] | CPC: |
C12N7/00 (EP,IL,KR,US);
A61K31/4745 (EP,IL,KR,US);
A61K35/768 (EP,IL,KR,US);
A61K31/165 (EP,IL,KR,US);
A61K31/553 (EP,IL,KR,US);
A61P35/00 (EP,IL,KR);
C07K16/2866 (US);
G01N33/6893 (KR);
A61K2300/00 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/21] | Title | German: | ONKOLYTISCHE SENECE-VALLEY-VIRUSTHERAPIE DER ZWEITEN GENERATION ZUSAMMENSETZUNGEN UND VERFAHREN DAFÜR | [2022/21] | English: | SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF | [2022/21] | French: | THÉRAPIE ONCOLYTIQUE DU VIRUS DE LA VALLÉE SÉNECA DE SECONDE GÉNÉRATION : COMPOSITION ET PROCÉDÉS ASSOCIÉS | [2022/21] | Entry into regional phase | 05.02.2022 | National basic fee paid | 05.02.2022 | Search fee paid | 05.02.2022 | Designation fee(s) paid | 05.02.2022 | Examination fee paid | Examination procedure | 05.02.2022 | Examination requested [2022/21] | 13.03.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 13.05.2024 | Amendment by applicant (claims and/or description) | 13.05.2024 | Date on which the examining division has become responsible | Request for further processing for: | The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application | 13.05.2024 | Request for further processing filed | 13.05.2024 | Full payment received (date of receipt of payment) Request granted | 14.06.2024 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 13.05.2024 | Request for further processing filed | 13.05.2024 | Full payment received (date of receipt of payment) Request granted | 23.05.2024 | Decision despatched | Fees paid | Renewal fee | 27.07.2022 | Renewal fee patent year 03 | 27.07.2023 | Renewal fee patent year 04 | 29.07.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI] - LITIAN YU ET AL, "A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models", NEURO-ONCOLOGY, OXFORD UNIVERSITY PRESS, US, (20110101), vol. 13, no. 1, doi:10.1093/NEUONC/NOQ14, ISSN 1522-8517, pages 14 - 27, XP009151110 [X] 6,7 * abstract * * page 24, line 8 * * page 17, column l, lines 4-6 * * page 24, column l, paragraph 2 * [I] 1-5,8-15 DOI: http://dx.doi.org/10.1093/neuonc/noq14 | [I] - JAYAWARDENA NADISHKA ET AL, "Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20181031), vol. 115, no. 46, doi:10.1073/pnas.1810664115, ISSN 0027-8424, XP093063272 [I] 1-15 * abstract * * page E10934, column l * DOI: http://dx.doi.org/10.1073/pnas.1810664115 | [I] - BACHRAN CHRISTOPHER ET AL, "Tumor Targeting and Drug Delivery by Anthrax Toxin", TOXINS, (20160701), vol. 8, doi:10.3390/toxins8070197, pages 1 - 16, XP093063275 [I] 1-15 * abstract * * page 2, paragraph 1 * DOI: http://dx.doi.org/10.3390/toxins8070197 | International search | [Y]WO2017096201 (MEMORIAL SLOAN KETTERING CANCER CENTER [US]) [Y] 1-8 and 18 * . Especially para [0004], para [0005], para [0008], para [0027], para [0028], para [0044], para [0045], para [0047], para [0052], para [0086], para [0090] and para [0091]. *; | [Y] - Chandra Partha K., Bao Lili, Song Kyoungsub, Aboulnasr Fatma M., Baker Darren P., Shores Nathan, Wimley William C., Liu Shuanghu, Hagedorn Curt H., Fuchs Serge Y., Wu Tong, Balart Luis A., Dash Srikanta, "HCV Infection Selectively Impairs Type I but Not Type III IFN Signaling", The American Journal of Pathology, (20140100), vol. 184, no. 1, pages 214 - 229, XP055785880 [Y] 1-8 and 18 * . Especially pg 224, col 1, para 3. * DOI: http://dx.doi.org/10.1016/j.ajpath.2013.10.005 |